2020年《系统性硬化症和COVID-19大流行:世界硬皮病基金会对患者管理的初步建议》解读  

Interpretation of Systemic Sclerosis and the COVID-19 Pandemic:World Scleroderma Foundation Preliminary Advice for Patient Management

作　　者：崔洁涵 杨林[1] 汪晓平[1] 何晶晶 彭晓欣 冯星 马隽 刘爱京[1,3] CUI Jiehan;YANG Lin;WANG Xiaoping;HE Jingjing;PENG Xiaoxin;FENG Xing;MA Jun;LIU Aijing(Department of Rheumatology and Immunology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Hebei Medical University,Shijiazhuang 050000,China;Hebei Research Center for Stem Cells Medical Translational Engineering,Shijiazhuang 050000,China;Department of Anatomy,Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院风湿免疫科,河北省石家庄市050000 [2]河北医科大学,河北省石家庄市050000 [3]河北省干细胞医学转化工程研究中心,河北省石家庄市050000 [4]河北医科大学解剖教研室,河北省石家庄市050000

出　　处：《中国全科医学》2021年第17期2218-2223,2229,共7页Chinese General Practice

基　　金：河北省医学科学研究课题计划(20190552)。

摘　　要：新型冠状病毒肺炎(COVID-19)仍在世界范围内流行,系统性硬化症(SSc)患者因常继发间质性肺疾病且广泛使用激素及免疫抑制剂而在疫情期间应受到关注,其一旦感染则面临着疾病恶化甚至死亡的风险。因此世界硬皮病基金会(WSF)针对COVID-19大流行提出了SSc患者的管理建议,本文通过对该建议进行解读与评析,对目前SSc合并COVID-19治疗手段进行了总结与展望,为SSc患者在COVID-19大流行下的临床治疗提供参考。Currently,COVID-19 continues to overwhelmingly hit almost all the countries of the world.It is noteworthy that patients with systemic sclerosis are considered to be a group at risk for disease deterioration and even death when they get infected COVID-19 due to the co-morbidity of interstitial lung disease and widespread use of glucocorticoids and immunosuppressive agents.In this case,the World Scleroderma Foundation put forward recommendations for the management of patients with SSc.We introduced and interpreted these recommendations,with a summary of present treatment strategies for SSc patients with COVID-19,aiming to provide more options for clinical management of these patients.

关 键 词：硬皮病 系统性 新型冠状病毒肺炎 系统性硬化症 间质性肺疾病 治疗 

分 类 号：R593.25[医药卫生—内科学] R512.99[医药卫生—临床医学]